Immunomodulatory News and Research

RSS

Low levels of vitamin D appear common in healthy children

Many healthy infants and toddlers may have low levels of vitamin D, and about one-third of those appear to have some evidence of reduced bone mineral content on X-rays, according to a report in the June issue of Archives of Pediatrics & Adolescent Medicine.

2 Jun 2008

Quality of care for inflammatory bowel disease patients can be improved

Inflammatory bowel disease (IBD) is a chronic recurrent gastrointestinal disease.

26 Feb 2008

New drug targets may fight tuberculosis and other bacterial infections in novel way

Over the course of the 20th Century, doctors waged war against infectious bacterial illness with the best new weapon they had: antibiotics.

28 Dec 2007

Paradigm shift in TB: virulence factors, not antibiotics

Over the course of the 20th Century, doctors waged war against infectious bacterial illness with the best new weapon they had: antibiotics.

27 Dec 2007

Oral drug sets a new survival standard for bone marrow cancer

Findings from two large, international clinical trials show "unprecedented" survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of bone marrow.

21 Nov 2007

Pfizer to acquire Coley Pharmaceutical Group

Pfizer has announced that it has entered into an agreement to acquire Coley Pharmaceutical Group, a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.

19 Nov 2007

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Celgene International Sarl has announced that it's oral cancer drug, Revlimid (lenalidomide) has been granted approval by the Swiss Agency for Therapeutic Products (Swissmedic) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.

5 Sep 2007

New TLR9 agonists patent for Dynavax Technologies

Dynavax Technologies Corporation has announced that the U.S. Patent Office has issued the company a broad composition of matter patent covering the company's proprietary second-generation TLR9 agonists.

17 Aug 2007

Liver center leading record number of studies to tackle hepatitis C

While many research institutions are suffering from funding cuts, Drs. Bruce R. Bacon and Adrian M. Di Bisceglie are chugging away with their usual tenacity.

27 Apr 2007

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

18 Apr 2007

MS patients not receiving medications to slow disease progression

Neurologists at Wake Forest University Baptist Medical Center have found that many patients diagnosed with multiple sclerosis (MS) are not taking or being prescribed drugs approved to treat the disease.

17 Apr 2007

Many US multiple sclerosis patients aren't receiving the latest drug therapies

Immunomodulatory agents (IMAs) could slow the progress of the disease, but are only prescribed in a minority of cases, and mostly by neurologists.

5 Apr 2007

Injection may prevent infertility in men receiving cancer chemotherapy

It may be possible to protect the testes of cancer patients against the loss of fertility caused by chemotherapy.

20 Jun 2006

Thalomid gets FDA approval to treat multiple myeloma

Thalomid (thalidomide) has been given a new lease of life following the United States Food and Drug Administration (FDA) approval for the drug to be used in combination with the steroid dexamethasone for the treatment of newly diagnosed multiple myeloma.

29 May 2006

Atorvastatin could prove an effective therapy for multiple sclerosis

Scientists at the University of California, San Francisco and Stanford University Medical Center are reporting compelling new evidence that the cholesterol-lowering drug atorvastatin could prove an effective therapy for preventing the progression of, and reversing the severity of, multiple sclerosis (MS).

20 Mar 2006

Bioniche granted patent for oligonucleotide technology

Bioniche Life Sciences has announced that it has been granted a European patent - EP1432450 - covering the composition and use of a novel oligonucleotide family for the treatment of cancer entitled: "Therapeutically Useful Triethyleneglycol Cholesteryl Oligonucleotides"

17 Mar 2006

Therapy for metastatic renal cell carcinoma remains inadequate

The recent FDA approvals of the tyrosine kinase inhibitors sorafenib and sunitinib based on their activity in metastatic renal cell carcinoma have excited the medical oncology community

9 Mar 2006

Identification of a factor in human milk that can block HIV-1 transmission

Mother to child transmission of HIV accounts for a large proportion of HIV infections in children, with many infected as a result of breastfeeding, which requires transfer of the virus across mucosal barriers. DC-SIGN, a DC lectin receptor, interacts with HIV and is found at high expression levels in tonsillar tissue.

20 Oct 2005

dnaJP1 - novel drug for the treatment of rheumatoid arthritis

Researchers at the University of California, San Diego (UCSD) School of Medicine have announced successful completion of Phase II clinical trials of a novel drug for the treatment of rheumatoid arthritis (RA), one that works without suppressing the patient's immune system.

16 Oct 2005

People who drink alcohol have a lower risk of non-Hodgkin's lymphoma

People who drink alcohol have a lower risk of non-Hodgkin's lymphoma (NHL) than non-drinkers, researchers at Yale's Department of Epidemiology and Public Health (EPH) write in an article published in Lancet Oncology.

15 Aug 2005